BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We are submitting to the exchange newspaper advertisements of Unaudited financial results of the Company for the quarter ended 31.12.2021, published in Financial Express (English) and Sanjay vani (Kannada) on 12th February 2022. BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are circulating the enclosed press release on the standalone and consolidated financial results of the Company for the quarter and half year ended 31.12.2021, announced by us on 10.02.2022. Please take the same on record. BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Outcome Of The Board Meeting
The Board of Directors of the Company has met to day and inter alia transacted the following business. Taken on record and approved the Unaudited financial results of the Company for the quarter ended 31.12.2021. Copy of the standalone and consolidated financial results along with the limited review reports with unmodified opinions issued by the statutory auditors of the Company is enclosed, for submission to the exchanges. The meeting commenced at 16.30 and concluded at 18.00 hours on 10.02.2022. BAL PHARMA LTD. - 524824 - Standalone & Consolidated Financial Results 31.12.2021
The Board of Directors of the Company has met to day and inter alia transacted the following business. Taken on record and approved the Unaudited financial results of the Company for the quarter ended 31.12.2021. Copy of the standalone and consolidated financial results along with the limited review reports with unmodified opinions issued by the statutory auditors of the Company is enclosed, for submission to the exchanges. The meeting commenced at 16.30 and concluded at 18.00 hours on 10.02.2022. BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended 31.12.2021.
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2022 ,inter alia, to consider and approve Unaudited financial results ( standalone & Consolidated ) for the quarter ended 31.12.2021. BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We are submitting to the exchange notices received from our R&T agents i.e TSR Darashaw Private Ltd, Mumbai, regarding loss of share certificates by one of our share holder. BAL PHARMA LTD. - 524824 - Shareholding for the Period Ended December 31, 2021
Bal Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Based on the certificate's received from our R&T agents i.e TSR Darashaw Pvt Ltd, we would like to confirm that the details of securities dematerialized / rematerialized during the quarter ended on 31.12.2021 have been furnished to all the stock exchanges where the equity shares of the Company are listed, within the prescribed time limit. The Share certificates received for dematerialization, if any has been mutilated and cancelled after due verification and the name of the depository has been substituted in the records as registered owner, within 15 days of the receipt of the certificate of security. BAL PHARMA LTD. - 524824 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- G RengarajanDesignation :- Chief Financial Officer BAL PHARMA LTD. - 524824 - Transfer Of Equity Shares To IEPF A/C
We would like to inform the exchanges that as per Rule 6 of Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules 2016, We have transferred 9,111 equity shares belonging to 59 shareholders of the Company who has not encased their dividend since last 7 consecutive years, to Investor Education and Protection Fund a/c (IEPF) for F.Y 2020.21. The List of Shareholders and their respective shareholding that was transferred to the IEPF a/c is updated on our website i.e www.balpharma.com.